LEADER 01319nas  2200445-a 450 
001 996417618103316
005 20230214213019.0
011   $a1473-157X
035   $a(OCoLC)43614561
035   $a(CKB)111088195230544
035   $a(CONSER)---00243081-
035   $a(EXLCZ)99111088195230544
100   $a19990112a19989999  ---            -
101 0 $aeng
181   $ctxt$2rdacontent
182   $cn$2rdamedia
200 00$aCNS drug news
210   $aChichester, West Sussex, UK ;$aPrinceton, NJ, USA $cEspicom Business Intelligence
311   $a1462-656X 
517 3 $aCentral nervous system drug news
606   $aDrugs$vPeriodicals
606   $aNeuropsychopharmacology$vPeriodicals
606   $aCentral Nervous System Agents
606   $aClinical Trials
606   $aDrug Approval
606   $aDrugs$2fast$3(OCoLC)fst00898761
606   $aNeuropsychopharmacology$2fast$3(OCoLC)fst01036504
608   $aPeriodical.
608   $aPeriodicals.$2fast
615  0$aDrugs
615  0$aNeuropsychopharmacology
615 12$aCentral Nervous System Agents.
615 22$aClinical Trials.
615 22$aDrug Approval.
615  7$aDrugs.
615  7$aNeuropsychopharmacology.
906   $aJOURNAL
912   $a996417618103316
996   $aCNS drug news$92236909
997   $aUNISA